An adult with newly diagnosed metastatic lung adenocarcinoma has an EGFR exon 19 deletion and has received no systemic treatment. Which dual targeted

Question

An adult with newly diagnosed metastatic lung adenocarcinoma has an EGFR exon 19 deletion and has received no systemic treatment. Which dual targeted regimen is now a NICE first-line option?

Accepted Answer

Use first-line amivantamab plus lazertinib for the sensitising EGFR mutation

Answer

Use first-line amivantamab plus carboplatin for a sensitising EGFR mutation

Answer

Use first-line lazertinib plus pembrolizumab without selecting by PD-L1 expression

Answer

Use amivantamab monotherapy after progression during first-line osimertinib treatment

Answer

Use first-line osimertinib plus durvalumab as the appraisal-defined dual regimen

Central Retinal Artery Occlusion — UKMLA MCQ

An adult with newly diagnosed metastatic lung adenocarcinoma has an EGFR exon 19 deletion and has received no systemic treatment. Which dual targeted regimen is now a NICE first-line option?